Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant RSV Vaccine (CHO Cell) in Adults
NCT07582796Phase 2Recruiting
- Sponsor
- Ab&B Bio-tech Co., Ltd.
- Start
- May 2026
- Primary completion
- Sep 2027
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant respiratory syncytial virus vaccine in respiratory syncytial virus infection (RSV), sponsored by Ab&B Bio-tech Co., Ltd.. Started May 2026; status: recruiting.
02
Drugs
recombinant respiratory syncytial virus vaccine
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT07582796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07582796.